Clopidogrel/Acetylsalicylic acid Teva

Country: Unjoni Ewropea

Lingwa: Ingliż

Sors: EMA (European Medicines Agency)

Ixtrih issa

Ingredjent attiv:

clopidogrel, Acetylsalicylic acid

Disponibbli minn:

Teva Pharma B.V.

Kodiċi ATC:

B01AC30

INN (Isem Internazzjonali):

clopidogrel, acetylsalicylic acid

Grupp terapewtiku:

combinations

Żona terapewtika:

Acute Coronary Syndrome; Myocardial Infarction

Indikazzjonijiet terapewtiċi:

Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). Clopidogrel/Acetylsalicylic acid Teva is a fixed‑dose combination medicinal product for continuation of therapy in:Non‑ST segment elevation acute coronary syndrome (unstable angina or non‑Q‑wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary interventionST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy

Sommarju tal-prodott:

Revision: 1

L-istatus ta 'awtorizzazzjoni:

Withdrawn

Data ta 'l-awtorizzazzjoni:

2014-09-01

Fuljett ta 'informazzjoni

                                59
B. PACKAGE LEAFLET
Medicinal product no longer authorised
60
PACKAGE LEAFLET: INFORMATION FOR THE USER
CLOPIDOGREL/ACETYLSALICYLIC ACID TEVA 75 MG/75 MG FILM-COATED TABLETS
clopidogrel/acetylsalicylic acid
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4. .
WHAT IS IN THIS LEAFLET
1.
What Clopidogrel/Acetylsalicylic acid Teva is and what it is used for
2.
What you need to know before you take Clopidogrel/Acetylsalicylic acid
Teva
3.
How to take Clopidogrel/Acetylsalicylic acid Teva
4.
Possible side effects
5.
How to store Clopidogrel/Acetylsalicylic acid Teva
6.
Contents of the pack and other information
1.
WHAT CLOPIDOGREL/ACETYLSALICYLIC ACID TEVA IS AND WHAT IT IS USED FOR
Clopidogrel/Acetylsalicylic acid Teva contains clopidogrel and
acetylsalicylic acid (ASA) and belongs
to a group of medicines called antiplatelet medicinal products.
Platelets are very small structures in the
blood which clump together during blood clotting. By preventing this
clumping in some types of blood
vessels (called arteries), antiplatelet medicinal products reduce the
chances of blood clots forming (a
process called atherothrombosis).
Clopidogrel/Acetylsalicylic acid Teva is taken by adults to prevent
blood clots forming in hardened
arteries which can lead to atherothrombotic events (such as stroke,
heart attack, or death).
You have been prescribed Clopidogrel/Acetylsalicylic acid Teva in
place of the two separate
medicines, clopidogrel and ASA, to help prevent blood clots because
you have experienced a severe
type of chest pain known as ‘unst
                                
                                Aqra d-dokument sħiħ
                                
                            

Karatteristiċi tal-prodott

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen
sulphate) and 75 mg of
acetylsalicylic acid (ASA).
Excipient with known effect:
Each film-coated tablet contains 102.6 mg of lactose (as lactose
monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet)
Yellow, film-coated capsule shaped tablets. The tablets have a length
of 14.0 mm and a width of
6.8 mm.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention
of atherothrombotic events in
adult patients already taking both clopidogrel and acetylsalicylic
acid (ASA).
Clopidogrel/Acetylsalicylic acid Teva is a fixed-dose combination
medicinal product for continuation
of therapy in:

Non-ST segment elevation acute coronary syndrome (unstable angina or
non-Q-wave
myocardial infarction) including patients undergoing a stent placement
following percutaneous
coronary intervention

ST segment elevation acute myocardial infarction in medically treated
patients eligible for
thrombolytic therapy
For further information please refer to section 5.1.
_ _
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
Posology

Adults and elderly population
Clopidogrel/Acetylsalicylic acid Teva should be given as a single
daily 75 mg/75 mg dose.
Clopidogrel/Acetylsalicylic acid Teva is used following initiation of
therapy with clopidogrel and
ASA given separately.
-
_In patients with non-ST segment elevation acute coronary syndrome_
(unstable angina or
non-Q-wave myocardial infarction): The optimal duration of treatment
has not been formally
established. Clinical trial data support use up to 12 months, and the
maximum benefit was seen
at 3 months (see section 5.1). If the use of the combination of
clopidogrel/acetylsalic
                                
                                Aqra d-dokument sħiħ
                                
                            

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Bulgaru 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Bulgaru 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Spanjol 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Spanjol 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ċek 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ċek 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Daniż 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Daniż 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ġermaniż 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ġermaniż 28-04-2017
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ġermaniż 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Estonjan 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Estonjan 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Grieg 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Grieg 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Franċiż 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Franċiż 28-04-2017
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Franċiż 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Taljan 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Taljan 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Latvjan 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Latvjan 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Litwanjan 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Litwanjan 28-04-2017
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Litwanjan 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ungeriż 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ungeriż 28-04-2017
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ungeriż 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Malti 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Malti 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Olandiż 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Olandiż 28-04-2017
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Olandiż 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Pollakk 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Pollakk 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Portugiż 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Portugiż 28-04-2017
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Portugiż 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Rumen 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Rumen 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Slovakk 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Slovakk 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Sloven 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Sloven 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Finlandiż 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Finlandiż 28-04-2017
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Finlandiż 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Svediż 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Svediż 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Norveġiż 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Norveġiż 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Iżlandiż 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Iżlandiż 28-04-2017
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Kroat 28-04-2017
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Kroat 28-04-2017

Fittex twissijiet relatati ma 'dan il-prodott